MediciNova Announces Initiation of a Phase Ib Clinical Trial for MN-221 in Patients With Stable,...

SAN DIEGO, Nov. 3, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:... [read full story]                    

powered by
Add Comment
There are also 1 related articles
View all news articles about*:
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies